Publication

Coronary Computed Tomography Angiography From Clinical Uses to Emerging Technologies JACC State-of-the-Art Review

Downloadable Content

Persistent URL
Last modified
  • 09/11/2025
Type of Material
Authors
    Khaled M Abdelrahman, National Heart, Lung, and Blood Institute, National Institutes of Health, BethesdaMarcus Y Chen, National Heart, Lung, and Blood Institute, National Institutes of Health, BethesdaAmit K Dey, National Heart, Lung, and Blood Institute, National Institutes of Health, BethesdaRenu Virmani, CVPath InstituteAloke Finn, Emory UniversityRamzi Y Khamis, Imperial College LondonAndrew D Choi, George Washington UniversityJames K Min, New York-Presbyterian HospitalMichelle C Williams, University of EdinburghAndrew J Buckler, Elucid BioimagingCharles A Taylor, HeartFlow IncCampbell Rogers, HeartFlow IncHabib Samady, Emory UniversityCharalambos Antoniades, University of OxfordLeslee Shaw, Emory UniversityMatthew J Budoff, Harbor-UCLA Medical CenterUdo Hoffmann, Harvard Medical SchoolRon Blankstein, Harvard Medical SchoolJagat Narula, Icahn School of Medicine at Mount SinaiNehal N Mehta, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda
Language
  • English
Date
  • 2020-09-08
Publisher
  • ELSEVIER SCIENCE INC
Publication Version
Copyright Statement
  • Published by Elsevier on Behalf of The American College of Cardiology Foundation.
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 76
Issue
  • 10
Start Page
  • 1226
End Page
  • 1243
Abstract
  • Evaluation of coronary artery disease (CAD) using coronary computed tomography angiography (CCTA) has seen a paradigm shift in the last decade. Evidence increasingly supports the clinical utility of CCTA across various stages of CAD, from the detection of early subclinical disease to the assessment of acute chest pain. Additionally, CCTA can be used to noninvasively quantify plaque burden and identify high-risk plaque, aiding in diagnosis, prognosis, and treatment. This is especially important in the evaluation of CAD in immune-driven conditions with increased cardiovascular disease prevalence. Emerging applications of CCTA based on hemodynamic indices and plaque characterization may provide personalized risk assessment, affect disease detection, and further guide therapy. This review provides an update on the evidence, clinical applications, and emerging technologies surrounding CCTA as highlighted at the 2019 National Heart, Lung and Blood Institute CCTA Summit.
Author Notes
  • Nehal N. Mehta, MD MSCE, Chief, Section of Inflammation and Cardiometabolic Disease, National Heart, Lung, and Blood Institute, 10 Center Drive, Clinical Research Center, Room 5-5140, Bethesda, MD 20892, USA. Email: nehal.mehta@nih.gov. Phone: (301) 827-0483, Fax: (301) 827-0915
Keywords

Tools

Relations

In Collection:

Items